Alzheimer's disease

R&D

The continued questions over new Alzheimer’s treatments

Hailed as a breakthrough after many years without new treatments for Alzheimer’s disease, a new generation of therapies for the condition have not been welcomed by payers.

News

FDA clears Rexulti as first drug for Alzheimer’s agitation

Lundbeck and Otsuka’s Rexulti has become the first drug to be approved by the FDA to treat agitation associated with Alzheimer’s disease, a common symptom of the neurodege

News

Five takeaways from the new donanemab data

Headlines about the results of TRAILBLAZER-ALZ2 trial of Eli Lilly’s Alzheimer’s drug candidate donanemab are spreading around the world, with some going as far as to sugg

News

Donanemab data “strongest yet” in Alzheimer’s

Eli Lilly has reported the results of its much-anticipated phase 3 trial of amyloid-targeting Alzheimer’s disease therapy donanemab, saying that almost half the patients t

R&D

Is biotech ready for the lecanemab opportunity?

The US Veterans Health Administration recently announced that it will cover the cost of Biogen’s lecanemab for veterans suffering from early stages of Alzheimer’s disease.

News

Rexulti backed for Alzheimer’s agitation by FDA adcomm

Otsuka and Lundbeck’s antidepressant Rexulti should be approved to treat Alzheimer’s disease-related agitation (AAD), according to FDA advisors – a move that could unlock

The continued questions over new Alzheimer’s treatments

FDA clears Rexulti as first drug for Alzheimer’s agitation

Five takeaways from the new donanemab data

Donanemab data “strongest yet” in Alzheimer’s

Is biotech ready for the lecanemab opportunity?

Rexulti backed for Alzheimer’s agitation by FDA adcomm

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Alzheimer's disease

Editor's Picks